All News

Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (neutrophil degranulation, ECM, tissue remodeling) involved in lupus nephritis Class II. @RheumNow #ACR24 https://t.co/kufd2zl9yc

https://x.com/AkhilSoodMD/status/1858211500739199121/photo/1

@kekuchinad A#1689 PFT ref equations -> inequities in SSc ILD Predict FVC uses age, ht, sex & race - higher % pred values -> underdx Race-specific v neutral equations: More black pts meet trial eligibility (69/57%), immunos (56/40), lung t, (14/9) @RheumNow #ACR24 #ACRBest https://t.co/40PFmdk3Xv

Is there a less invasive approach to evaluate lupus nephritis? Abstract 1683 highlights the potential role of 68Ga-FAPI PET imaging in evaluating for lupus nephritis. FAPI uptake ↑ in pts with lupus nephritis vs HC. Correlated with IFN -α and IFN-γ pathways. @RheumNow #ACR24

Very neat simulated model of GC regimens in AAV pt on fixed RTX by @zach_wallace_md and co Over 5 years: - No difference in relapse btwn standard GC vs. minimal GC + avacopan - Higher DMII rates in standard group Adds to trial + real world data @RheumNow #ACR24 Abst 1598

Will my patient with lupus nephritis respond well to induction therapy? Abstract 1685: Aundhia et al demonstrate the promising utility of RAIL to predict complete renal response in patients with lupus nephritis (Class III or IV +/- V) @RheumNow #ACR24 https://t.co/JBldrrwUhN

https://x.com/AkhilSoodMD/status/1858213010609000758/photo/1

#1689: race-neutral 🫁 function equations in SSc improve equity: 🔹 Race-specific equations underestimate disease severity in Black patients. 🔹 Switching to race-neutral reclassified 45% of Black patients to more severe, 16% of White patients to less severe @RheumNow #acr24 https://t.co/BfK2PsCMX5

https://x.com/CaoilfhionnMD/status/1858213164443119768/photo/1

Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE Belimumab ~ 600% increase!! @RheumNow #ACR24 abst#1259 https://t.co/norl1xk2KF

https://x.com/bella_mehta/status/1858205209165541866/photo/1

#SLE treatments #ACR24: Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (BLyS) and proliferation-inducing ligand(APRIL)) Both improved disease activity with no difference in efficacy Belimumab had lower infection rates @RheumNow abst1544

More data from PAISLEY, deucravacitinib in SLE Small but significant benefit w/respect to joints, a little disappointing tbh Would like to see this for all manifestations ie pericarditis, pleuritis, etc Anyone have an infographic or useful chart? #ACR20 @RheumNow Abstr#1552 https://t.co/tXUoUtssxo

Low uptake of SGLT2i in Lupus nephritis SGLT2i users had similar adverse event rates as ACEi/ARB users SGLT2i users experienced more weight loss #ACR24 @rheumnow abst#1534 https://t.co/tB5o7tyhu5

https://x.com/bella_mehta/status/1858207474039292036/photo/1

Study on SLE and NMO overlap: Higher risk of acute cystitis & severe sepsis in hospitalized patients SLE/NMO overlap patients 3x more likely to develop acute cystitis 2x more likely to develop severe sepsis #ACR24 @RheumNow abst#1529

Study on SLE treatments: Compared adverse events of anifrolumab vs. belimumab Similar risks for mortality, sepsis, herpes zoster, dialysis, MACE, PE/VTE, COVID-19, URI, pneumonia, and mental illness #ACR24 @RheumNow abst#1527

Smoking and Rx progression in PsA? -Prospective Canadian cohort of 1736 PsA pts. -Older age, BL SJC, dactylitis, erosions and high ESR were associated with Rx progression. 🚨Cigarette smoking did not appear to be associated with the Rx progression in PsA. Abst#1436 #ACR24… https://t.co/J2IogqOlx8 https://t.co/U6SRmbOE6o

Study on severe lymphopenia in SLE: - Assessed incidence, risk factors, and outcomes - 11.52% of SLE patients experienced severe lymphopenia - Higher infection rates during severe lymphopenia period = No opportunistic infections observed #ACR24 abst#1519 @rheumnow @HSSProfEd

Study on pregnancy outcomes in SLE with thrombocytopenia: Higher disease activity, pregnancy loss, and stillbirth rates Identified risk factors: Anti-β2GP-I positivity and higher SLEDAI score #ACR24 abst#1487 @RheumNow

Study on cardiovascular deaths in SLE: - Analyzed 1999-2020 data - Overall decline in mortality rates, but recent increase since 2014 - Higher rates in women and African Americans - Geographic disparities noted #ACR24 abst#0998 @rheumnow https://t.co/dpjsl0gI0x

Post hoc analysis of INVIGORATE-1 trial evaluated predictors of ASAS40 response in axSpA pts who received IV SEC ⬆️back pain, long dse duration, ⬇️BMI: assoc w/ ⬆️ clinical response BL enthesitis, older age, ⬆️dse activity: assoc w/ ⬇️ clinical response @RheumNow #ACR24 abs1482 https://t.co/528A5lXVKl

#Upadacitinib rises ‘ Up’ in all subgroups of #GCA Subset of overall #RCT of #rinvoq w more reduction of #steroids vs placebo+ slower #prednisone taper Consistent results best in UPA 15 mg >UPA 7.5mg/d > #placebo #ACR24 #ACRBest @RheumNow @ACRheum abst#1695 https://t.co/dA7RkNmWFd

https://x.com/Janetbirdope/status/1858210971937841222/photo/1

RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.

Salivary glands in #Sjogens #Disease Have persistent #IFN signature Abnormal morphology ⬇️ secretory ability In Differentiated salivary gland organoids DSGO May aid in drug screening Would drugs that ⬇️ #interferon help #Sjogren’s Abst#1406 @RheumNow @ACRheum #ACR24 https://t.co/dppp0tyFk5

https://x.com/Janetbirdope/status/1858202665211089048/photo/1

Topics

All News

Do you get our email newsletter?